nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.12.2014

Skeletal muscle glucose metabolism and inflammation in the development of the metabolic syndrome

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Insulin resistance and metabolic dysfunction in skeletal muscle play a major role in the development of the metabolic syndrome and type 2 diabetes. Numerous mechanisms have been proposed to explain the pathophysiology of obesity-linked metabolic dysfunction and this review will focus on the contributing role of adiponectin and inflammation. The beneficial effects of adiponectin on both insulin action and inflammation are now well documented and will be reviewed. More recent work provided new insights into adiponectin signaling mechanisms. The development of strategies to mimic adiponectin action holds promise that adiponectin-based compounds may translate into effective therapeutic applications. We will also discussed the novel role of long chain ω-3 PUFA-derived resolution mediators, which in addition to resolving inflammation, can also exert glucoregulatory effects in models of obesity and insulin resistance. We will focus on one resolution mediator, protectin DX (PDX), which was recently shown to act as a muscle interleukin-6 secretagogue. PDX and its isomer PD1 also enhance adiponectin expression and action. Ultimately, it is via a better understanding the molecular mechanisms of action via which inflammation, insulin resistance and metabolic dysfunction occur in skeletal muscle, and also how they crosstalk with each other, that we can generate new and improved therapies for obesity-linked metabolic complications.

Sherwin R, Jastreboff AM. Year in diabetes 2012: The diabetes tsunami. J Clin Endocrinol Metab. 2012;97(12):4293–301. doi:10.1210/jc.2012-3487.PubMedCentralCrossRefPubMed

Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010;2010:476279. doi:10.1155/2010/476279.PubMedCentralCrossRefPubMed

Raschke S, Eckel J. Adipo-myokines: Two sides of the same coin–mediators of inflammation and mediators of exercise. Mediat Inflamm. 2013;2013:320724. doi:10.1155/2013/320724.CrossRef

Henriksen T, Green C, Pedersen BK. Myokines in myogenesis and health. Recent Patents Biotechnol. 2012;6(3):167–71.CrossRef

Xu E, Schwab M, Marette A. Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance. Rev Endocr Metab Disord. 2014;15(1):79–97. doi:10.1007/s11154-013-9282-4.CrossRefPubMed

Fan W, Atkins AR, Yu RT, Downes M, Evans RM. Road to exercise mimetics: Targeting nuclear receptors in skeletal muscle. J Mol Endocrinol. 2013;51(3):T87–T100. doi:10.1530/JME-13-0258.CrossRefPubMed

Liu Y, Sweeney G. Adiponectin action in skeletal muscle. Best Pract Res Clin Endocrinol Metab. 2014;28(1):33–41. doi:10.1016/j.beem.2013.08.003.CrossRefPubMed

Scheid MP, Sweeney G. The role of adiponectin signaling in metabolic syndrome and cancer. Rev Endocr Metab Disord. 2014;15(2):157–67. doi:10.1007/s11154-013-9265-5.CrossRefPubMed

Liu Y, Retnakaran R, Hanley A, Tungtrongchitr R, Shaw C, Sweeney G. Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in Thai subjects. J Clin Endocrinol Metab. 2007;92(11):4313–8. doi:10.1210/jc.2007-0890.CrossRefPubMed

10.

Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab. 2013;2(3):133–41. doi:10.1016/j.molmet.2013.04.001.PubMedCentralCrossRefPubMed

11.

Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185–96. doi:10.1016/j.cmet.2013.01.001.CrossRefPubMed

12.

Kuoppamaa H, Skrobuk P, Sihvo M, Hiukka A, Chibalin AV, Zierath JR, et al. Globular adiponectin stimulates glucose transport in type 2 diabetic muscle. Diabetes Metab Res Rev. 2008;24(7):554–62. doi:10.1002/dmrr.883.CrossRefPubMed

13.

Cheng KK, Lam KS, Wang B, Xu A. Signaling mechanisms underlying the insulin-sensitizing effects of adiponectin. Best Pract Res Clin Endocrinol Metab. 2014;28(1):3–13. doi:10.1016/j.beem.2013.06.006.CrossRefPubMed

14.

Liu Y, Turdi S, Park T, Morris NJ, Deshaies Y, Xu A, et al. Adiponectin corrects high-fat diet-induced disturbances in muscle metabolomic profile and whole-body glucose homeostasis. Diabetes. 2013;62(3):743–52. doi:10.2337/db12-0687.PubMedCentralCrossRefPubMed

15.

Combs TP, Marliss EB. Adiponectin signaling in the liver. Rev Endocr Metab Disord. 2014;15(2):137–47. doi:10.1007/s11154-013-9280-6.PubMedCentralCrossRefPubMed

16.

Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: A review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014;28(1):15–23. doi:10.1016/j.beem.2013.09.003.CrossRefPubMed

17.

Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516–23. doi:10.1038/ncb1404.CrossRefPubMed

18.

Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes. 2007;56(5):1387–94. doi:10.2337/db06-1580.CrossRefPubMed

19.

Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332–9. doi:10.1038/nm1557.CrossRefPubMed

20.

Bjursell M, Ahnmark A, Bohlooly YM, William-Olsson L, Rhedin M, Peng XR, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes. 2007;56(3):583–93. doi:10.2337/db06-1432.CrossRefPubMed

21.

Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca (2+) and AMPK/SIRT1. Nature. 2010;464(7293):1313–9. doi:10.1038/nature08991.CrossRefPubMed

22.

Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005;48(1):132–9. doi:10.1007/s00125-004-1609-y.CrossRefPubMed

23.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–95. doi:10.1038/nm788.CrossRefPubMed

24.

Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98(4):2005–10. doi:10.1073/pnas.041591798.PubMedCentralCrossRefPubMed

25.

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762–9. doi:10.1038/nature01705.CrossRefPubMed

26.

Dadson K, Turdi S, Hashemi S, Zhao J, Polidovitch N, Beca S et al. Adiponectin is required for cardiac MEF2 activation during pressure overload induced hypertrophy. Journal of Molecular & Cellular Cardiology. 2014;submitted.

27.

Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, et al. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab. 2006;4(1):75–87. doi:10.1016/j.cmet.2006.05.002.PubMedCentralCrossRefPubMed

28.

Gulli RA, Tishinsky JM, MacDonald T, Robinson LE, Wright DC, Dyck DJ. Exercise restores insulin, but not adiponectin, response in skeletal muscle of high-fat fed rodents. Am J Physiol Regul Integr Comp Physiol. 2012;303(10):R1062–70. doi:10.1152/ajpregu.00176.2012.CrossRefPubMed

29.

Mullen KL, Tishinsky JM, Robinson LE, Dyck DJ. Skeletal muscle inflammation is not responsible for the rapid impairment in adiponectin response with high-fat feeding in rats. Am J Physiol Regul Integr Comp Physiol. 2010;299(2):R500–8. doi:10.1152/ajpregu.00080.2010.CrossRefPubMed

30.

Mullen KL, Smith AC, Junkin KA, Dyck DJ. Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat-fed rats. Am J Physiol Endocrinol Metab. 2007;293(1):E83–90. doi:10.1152/ajpendo.00545.2006.CrossRefPubMed

31.

Mullen KL, Pritchard J, Ritchie I, Snook LA, Chabowski A, Bonen A, et al. Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am J Physiol Regul Integr Comp Physiol. 2009;296(2):R243–51. doi:10.1152/ajpregu.90774.2008.CrossRefPubMed

32.

Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004;279(29):30817–22. doi:10.1074/jbc.M402367200.CrossRefPubMed

33.

Fang X, Palanivel R, Zhou X, Liu Y, Xu A, Wang Y, et al. Hyperglycemia- and hyperinsulinemia-induced alteration of adiponectin receptor expression and adiponectin effects in L6 myoblasts. J Mol Endocrinol. 2005;35(3):465–76. doi:10.1677/jme.1.01877.CrossRefPubMed

34.

Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia. 2004;47(5):816–20. doi:10.1007/s00125-004-1359-x.CrossRefPubMed

35.

Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B, et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia. 2004;47(5):917–25. doi:10.1007/s00125-004-1394-7.CrossRefPubMed

36.

Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding proteins–recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 2010;584(20):4280–6. doi:10.1016/j.febslet.2010.09.035.CrossRefPubMed

37.

Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, et al. Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure. Heart. 2011;97(17):1403–9. doi:10.1136/hrt.2011.226373.CrossRefPubMed

38.

Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, et al. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem. 2009;284(46):31608–15. doi:10.1074/jbc.M109.010355.PubMedCentralCrossRefPubMed

39.

Marinho R, Ropelle ER, Cintra DE, De Souza CT, Da Silva AS, Bertoli FC, et al. Endurance exercise training increases APPL1 expression and improves insulin signaling in the hepatic tissue of diet-induced obese mice, independently of weight loss. J Cell Physiol. 2012;227(7):2917–26. doi:10.1002/jcp.23037.CrossRefPubMed

40.

Li FY, Lam KS, Xu A. Therapeutic perspectives for adiponectin: An update. Curr Med Chem. 2012;19(32):5513–23.CrossRefPubMed

41.

Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: Evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci. 2009;30(5):234–9. doi:10.1016/j.tips.2009.02.004.CrossRefPubMed

42.

Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493–9. doi:10.1038/nature12656.CrossRefPubMed

43.

Vu V, Riddell MC, Sweeney G. Circulating adiponectin and adiponectin receptor expression in skeletal muscle: Effects of exercise. Diabetes Metab Res Rev. 2007;23(8):600–11. doi:10.1002/dmrr.778.CrossRefPubMed

44.

Farias JM, Maggi RM, Tromm CB, Silva LA, Luciano TF, Marques SO, et al. Exercise training performed simultaneously to a high-fat diet reduces the degree of insulin resistance and improves adipoR1-2/APPL1 protein levels in mice. Lipids Health Dis. 2012;11:134. doi:10.1186/1476-511X-11-134.PubMedCentralCrossRefPubMed

45.

White PJ, Marette A. Inflammation-Induced Insulin Resistance in Obesity: When Immunity Affects Metabolic Control. In: Hawley JA, Zierath JR, editors. Physical activity and type 2 diabetes: therapeutic effects and mechanisms of action. 2008. p. 83–106.

46.

Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001;7(10):1138–43.CrossRefPubMed

47.

Zhang X, Xu A, Chung SK, Cresser JH, Sweeney G, Wong RL, et al. Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes. 2011;60(2):486–95. doi:10.2337/db10-0650.PubMedCentralCrossRefPubMed

48.

Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333–6.CrossRefPubMed

49.

Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med. 2004;10(10):1128–32.CrossRefPubMed

50.

Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003;27:S49–52. doi:10.1038/sj.ijo.08025010802501. Suppl 3.CrossRefPubMed

51.

Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest. 2004;114(6):823–7.PubMedCentralCrossRefPubMed

52.

Stables MJ, Gilroy DW. Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res. 2011;50(1):35–51. doi:10.1016/j.plipres.2010.07.005.CrossRefPubMed

53.

Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med. 2010;268(1):15–24. doi:10.1111/j.1365-2796.2010.02235.x.PubMed

54.

Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol. 2005;6(12):1191–7. doi:10.1038/ni1276.CrossRefPubMed

55.

Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: Assignments of dihydroxy-containing docosatrienes. J Immunol. 2006;176(3):1848–59.CrossRefPubMed

56.

Chen P, Fenet B, Michaud S, Tomczyk N, Vericel E, Lagarde M, et al. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 2009;583(21):3478–84. doi:10.1016/j.febslet.2009.10.004.CrossRefPubMed

57.

Balas L, Guichardant M, Durand T, Lagarde M. Confusion between protectin D1 (PD1) and its isomer protectin DX (PDX). An overview on the dihydroxy-docosatrienes described to date. Biochimie. 2013. doi:S0300-9084 (13) 00402-1 10:1016/j.biochi.2013.11.006.

58.

Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: Fat-1 mice convert n-6 to n-3 fatty acids. Nature. 2004;427(6974):504. doi:10.1038/427504a 427504a.CrossRefPubMed

59.

White PJ, Arita M, Taguchi R, Kang JX, Marette A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes. 2010;59(12):3066–73. doi:10.2337/db10-0054.PubMedCentralCrossRefPubMed

60.

Gonzalez-Periz A, Planaguma A, Gronert K, Miquel R, Lopez-Parra M, Titos E, et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 2006;20(14):2537–9. doi:10.1096/fj.06-6250fje.CrossRefPubMed

61.

Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer’s disease models. PLoS One. 2011;6(1):e15816. doi:10.1371/journal.pone.0015816.PubMedCentralCrossRefPubMed

62.

Claria J, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol. 2012;189(5):2597–605. doi:10.4049/jimmunol.1201272.PubMedCentralCrossRefPubMed

63.

Neuhofer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes. 2013;62(6):1945–56. doi:10.2337/db12-0828.PubMedCentralCrossRefPubMed

64.

White PJ, St-Pierre P, Charbonneau A, Mitchell PL, St-Amand E, Marcotte B, et al. Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis. Nat Med. 2014;20(6):664–9. doi:10.1038/nm.3549.CrossRefPubMed

65.

Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55(10):2688–97. doi:10.2337/db05-1404.CrossRefPubMed

66.

Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004;53(7):1643–8.CrossRefPubMed

Titel: Skeletal muscle glucose metabolism and inflammation in the development of the metabolic syndrome
Publikationsdatum: 01.12.2014
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 4/2014
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-014-9296-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Fat sensing and metabolic syndrome

Genetics of metabolic syndrome

Ectopic visceral fat: A clinical and molecular perspective on the cardiometabolic risk

Metabolic syndrome and lifestyle modification

Metabolic syndrome and the environmental pollutants from mitochondrial perspectives